207 related articles for article (PubMed ID: 27888884)
41. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.
Pelicci PG; Knowles DM; Magrath I; Dalla-Favera R
Proc Natl Acad Sci U S A; 1986 May; 83(9):2984-8. PubMed ID: 3458257
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
43. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
[TBL] [Abstract][Full Text] [Related]
44. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.
Cardone M; Kandilci A; Carella C; Nilsson JA; Brennan JA; Sirma S; Ozbek U; Boyd K; Cleveland JL; Grosveld GC
Mol Cell Biol; 2005 Mar; 25(6):2395-405. PubMed ID: 15743832
[TBL] [Abstract][Full Text] [Related]
45. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
46. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
47. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
Mossafa H; Damotte D; Jenabian A; Delarue R; Vincenneau A; Amouroux I; Jeandel R; Khoury E; Martelli JM; Samson T; Tapia S; Flandrin G; Troussard X
Leuk Lymphoma; 2006 Sep; 47(9):1885-93. PubMed ID: 17065002
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
[TBL] [Abstract][Full Text] [Related]
49. Molecular resemblance of an AIDS-associated lymphoma and endemic Burkitt lymphomas: implications for their pathogenesis.
Haluska FG; Russo G; Kant J; Andreef M; Croce CM
Proc Natl Acad Sci U S A; 1989 Nov; 86(22):8907-11. PubMed ID: 2682665
[TBL] [Abstract][Full Text] [Related]
50. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
51. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
52. The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.
D'Andrea A; Gritti I; Nicoli P; Giorgio M; Doni M; Conti A; Bianchi V; Casoli L; Sabò A; Mironov A; Beznoussenko GV; Amati B
Oncotarget; 2016 Nov; 7(45):72415-72430. PubMed ID: 27635472
[TBL] [Abstract][Full Text] [Related]
53. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma.
Boffa LC; Cutrona G; Cilli M; Mariani MR; Matis S; Pastorino M; Damonte G; Millo E; Roncella S; Ferrarini M
Oligonucleotides; 2005; 15(2):85-93. PubMed ID: 15989423
[TBL] [Abstract][Full Text] [Related]
54. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
[TBL] [Abstract][Full Text] [Related]
55. Burkitt lymphoma presenting as a mass in the thyroid gland: a clinicopathologic study of 7 cases and review of the literature.
Quesada AE; Liu H; Miranda RN; Golardi N; Billah S; Medeiros LJ; Jaso JM
Hum Pathol; 2016 Oct; 56():101-8. PubMed ID: 27257042
[TBL] [Abstract][Full Text] [Related]
56. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
57. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
Dunleavy K
Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
[TBL] [Abstract][Full Text] [Related]
58. BCL-W has a fundamental role in B cell survival and lymphomagenesis.
Adams CM; Kim AS; Mitra R; Choi JK; Gong JZ; Eischen CM
J Clin Invest; 2017 Feb; 127(2):635-650. PubMed ID: 28094768
[TBL] [Abstract][Full Text] [Related]
59. Burkitt lymphoma in the mouse.
Kovalchuk AL; Qi CF; Torrey TA; Taddesse-Heath L; Feigenbaum L; Park SS; Gerbitz A; Klobeck G; Hoertnagel K; Polack A; Bornkamm GW; Janz S; Morse HC
J Exp Med; 2000 Oct; 192(8):1183-90. PubMed ID: 11034608
[TBL] [Abstract][Full Text] [Related]
60. Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry.
Mandelker DL; Dorfman DM; Li B; Pozdnyakova O
Leuk Lymphoma; 2014 Nov; 55(11):2592-6. PubMed ID: 24397618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
